Neuralstem CEO Attending 2013 Rodman & Renshaw Conference
Sept 3, 2013 6:08:29 GMT -8
Post by DJ on Sept 3, 2013 6:08:29 GMT -8
ROCKVILLE, Md., Sept. 3, 2013 /PRNewswire/ – Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 15th annual Rodman & Renshaw Healthcare Conference on Tuesday, September 10, at 11:40 a.m. EST, in Room 7.03, 7th Floor, of the Millennium Broadway Hotel in New York City. Garr will provide an overview of the company’s upcoming NSI-566 cell therapy clinical trials, including ALS Phase II, ischemic stroke Phase I/II, and chronic and acute spinal cord injury Phase I. He will also provide an update on the novel neurogenic small molecule drug, NSI-189, Phase Ib clinical trial in major depressive disorder. To view the live webcast, visit Neuralstem’s Investor Center at www.neuralstem.com, or: wsw.com/webcast/rrshq23/CUR.
About Neuralstem
Neuralstem’s patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, in February 2013, and has received FDA approval to begin Phase II. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.
In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord injury in January 2013.
Neuralstem’s patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, in February 2013, and has received FDA approval to begin Phase II. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.
In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord injury in January 2013.
Click here to read more - Neuralstem President And CEO To Present At The 2013 Rodman & Renshaw Annual Healthcare Conference